The Tanzanian diabetic retinopathy trial results were published in The Lancet Global Health by lead author Dr. Charles R. Cleland and research colleagues.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Barrister Peter Mant KC stated at the Lampard Inquiry that clinical effectiveness claims made by Oxevision manufacturer Lio Health were based on unverified anecdotes and unbacked by statistical evidence.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Researchers trained and validated the FAHR-Face survival prediction tools using photographs of over 30,000 cancer patients with known medical outcomes.

In the Swedish primary care trial, the Dermalyser app achieved an overall area under the ROC curve of 0.960 with 95.2% sensitivity and 84.5% specificity for distinguishing melanoma.

In the U.K. hospital study, the AI device demonstrated sensitivity for malignancy exceeding 97% across all skin cancer types and achieved a specificity of 72.1%.

The FAHR-FaceAge tool demonstrated biological age estimation correlation scores across racial groups of 0.86 for White, 0.81 for Black, 0.86 for Asian, and 0.91 for Hispanic individuals.

FAHR-FaceAge and FAHR-FaceSurvival yield weakly correlated predictions, and combining both measures improved survival-model fit in external validation testing.

Researchers validated the FAHR-FaceSurvival prediction model in an external cohort of nearly 4,900 cancer patients in the Netherlands.

In a validation trial of 3,820 cancer patients, 64 of the 122 patients assigned the highest FAHR-FaceSurvival risk scores died within 90 days, compared to 20 of 975 in the lowest-risk group.

University of Surrey machine learning expert Prof. Miroslaw Bober cautioned that the technology remains a proof of concept that requires further testing across hospitals before clinical deployment.

When evaluated against the AI model TotalSegmentator, the Percival model flagged conditions including pancreatic cancer, cirrhosis, and bacterial pneumonia significantly more reliably.

The findings and technical specifications regarding the Percival model were published by lead author Cameron A. Beeche and senior author Walter Witschey in the journal npj Digital Medicine.

More young people need to get their brain scanned

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider